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we achieved what we set out to do, have the consequences of 
treatment been worth the outcome and is this economically viable. 
The collection of relevant data and its intelligent use is critical. Data 
that allows measurement of the impact of side effects of treatments 
both short and long term along a patients entire continuum of care, 
their global quality of life, the economic impact across the board and 
whether outcomes have influenced practice,  and policy  are all 
important. Knowing how cancer and treatment affect individuals is 
critical in trying to determine whether any intervention is effective, 
tolerable and acceptable. The Cancer Outcomes Measurement 
Working Group (COMWG) has provided a more inclusive method of 
global assessment(3). This Group describes current best practices and 
recommendations for assessing the following three outcomes across 
the continuum of care: health-related quality of life; economic 
burden; and patient satisfaction; 
The Radiation Oncology community has developed a scoring system for 
recording Common Toxicity Criteria both for acute and long term 
symptoms and collection of quality of life data in radiation oncology 
clinical trials is becoming routine(4). A number of radiation oncology 
and medical oncology trials groups have consumers involved in the 
development of trials and on the trial management committees along 
with experts in quality of life.   
For Interventional Oncology, having access to alarge and relevant data 
repository that allows for such global evaluation iscritical. Expanding 
data collection beyond the RECIST criteria to encompass themore 
global measures discussed above needs to become routine if 
interventional oncology treatments are to become incorporated into 
mainstream care, funded andvalued. 
1. Breakaway: The global burden of cancer—challenges and 
opportunities.  Economist Intelligence Unit Ltd 2009 
2. www.RECIST.com 
3. outcomes.cancer.gov/areas/assessment/comwg.html 
4. ctep.cancer.gov/reporting/ctc.html 
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Purpose/Objective: MRI has a high sensitivity for tumor detection and 
a good correlation with histopathology findings. The precision of 
preoperative target volume delineation on newly developed 3D supine 
CE-MRI was compared to preoperative delineation on CE-CT in 
patients treated with breast-conserving therapy.  
Materials and Methods: We tested a newly developed 3D high 
resolution MRI protocol for target volume delineation in RT supine 
position in 14 cT1-2N0 patients. Gross tumor volumes (GTVs) were 
delineated by 4 experienced breast radiation oncologists, following 
written delineation instructions, on preoperative contrast-enhanced 
(CE) CT (1x1 mm2 in plane resolution, 3 mm slice thickness) and 3D 
CE-MRI (voxel size 1.2x1.2x1.2 mm3). To assess whether differences in 
GTV delineation were also clinically relevant, clinical target volumes 
(CTVs) were created by addition of a 1.5 cm margin around the tumor 
volume excluding the skin and chest wall. Interobserver variability 
(IOV) was assessed by calculating the conformity index (CI) and the 
center of mass distance (dCOM) for both the GTV and CTV in each 
patient. Tumor characteristics on CE-CT and CE-MRI were assessed 
and scored by an experienced breast radiologist.  
Results: In figure 1, target volume delineations of the 4 observers are 
shown on both preoperative CE-CT and CE-MRI in the same patient.  
The median CI of the GTV was higher on CE-MRI compared to CE-CT 
(Table 1). After expansion to the CTV, this difference in CI was no 
longer statistically significant. However, an incorrect GTV was 
delineated on CE-CT in 2/14 patients (14%) by multiple observers (1/4 
and 3/4 observers in each misdelineated patient). This resulted in 
high ranges of the CI on CE-CT. 
Tumor shapes were rated as more irregular and spiculated on CE-MRI. 
This did not result in a decreased CI on CE-MRI. A uniform volume 
expansion of GTV to CTV resulted in larger volumes on CE-MRI 
compared to CE-CT. 
No difference in median dCOM was observed between both image 
modalities. 
 
 
 
CI Conformity Index, GTV gross tumor volume, CTV clinical target 
volume, dCOM center of mass distance. Mean volume and dCOM were 
calculated per patient, median values were calculated over the 
included patient population. 
Conclusions: Preoperative target volume delineation showed a higher 
precision on 3D CE-MRI compared to CE-CT. A more irregular and 
spiculated tumor was visualized on CE-MRI without a decrease of 
interobserver agreement. Future studies will focus on using 
preoperative CE-MRI guided delineation in preoperative, as well as 
additional information in postoperative, whole or accelerated partial 
breast irradiation. 
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Purpose/Objective: START A and START B studies have demonstrated 
a similar toxicity obtained by hypofractionation and standard 
fractionation in whole breast adjuvant radiotherapy. The aim of this 
study is the evaluation of hypofractionation effect on toxicity in our 
breast cancer patients.  
Materials and Methods: From 02/2009 to 01/2012 500 patients were 
treated with hypofractionated whole breast radiotherapy, 40 Gy/15 
fractions, delivered in 3 weeks, in our institution. Five patients had 
bilateral treatment. The median patient age was 62 yrs(28-91yrs). 
Table 1 Parameters of interobserver variability (n=14) 
 CT MRI  
 Median Range Median Range p-
value 
Mean volume 
(cm3) 
GTV  
CTV  
2.9 
54.0 
0.5 – 14.9  
30.3 –
112.8  
2.6  
60.9 
0.7 – 17.0 
34.5 –
129.4 
0.47 
0.02 
Conformity index 
GTV  
CTV  
0.52 
0.81 
0.24 – 0.67 
0.38 – 0.85 
0.60  
0.82  
0.48 – 0.74 
0.77 – 0.87 
<0.01 
0.11 
Mean dCOM (mm)  
GTV  
CTV  
1.5 
1.7 
0.6 – 39.6 
1.1 – 39.4  
1.2 
1.7 
0.5 – 2.3  
0.8 – 3.4 
0.08 
0.60 
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A median number of 4 segments was used (2-12) within a tangential 
two field irradiation technique. 357 (70,69%) of breasts needed ≥4 
segments to obtain a homogeneous dose. To report the acute toxicity 
(6 months follow up included), the RTOG/EORTC scale was used, while 
for late toxicity the SOMA LENT scale was used. 
Results: The median follow-up of this group of patients was 11 mts(1-
37 mts). One patient was dead at the last follow up, with distant 
metastases and 7 presented progressive disease: 5 distant, 1 local and 
1 infrapectoral. 
The toxicities were: 
 
Toxicity 
grade 
End of RT 
(505 pts) 
At 6 mts 
(420 pts) 
At 12 mts 
(232 pts) 
At ≥24 mts 
(54 pts) 
G0 119 327 203 52 
G1 327 92 28 2 
G2 55 1 1 1 
G3 4 0 0 0 
 
Twenty-one of 505 pts(4,16%) presented a delayed acute toxicity, 5-30 
days after the end of radiotherapy. 
Toxicity was intended as skin discoloration, oedema and fibrosis. No 
lung or heart toxicity were recorded. 
Conclusions: The hypofractionated FIMRT regimen (2,67 Gy/fr) used 
for WBRT in our institution allowed us to obtain a good acute and late 
toxicity, better than historical standard fractionation results, with no 
treatment interruptions.  
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Purpose/Objective: The FAST-Forward trial is a multicentre phase III 
trial comparing a 1-week course of curative breast radiotherapy (RT) 
against a standard 3-week schedule (ISRCTN19906132). The purpose of 
this study was to assess the applicability of field-based (FB) and 
volume based (VB) PTV for dosimetric data analysis and to evaluate 
the consistency of the results reported using them. 
Materials and Methods: The ongoing QA programme for the FAST-
Forward trial involves retrospective individual case reviews to be 
carried out and for the completion of a number of dose objectives 
reported for the treated breast volume and organs at risk. Depending 
upon the centre’s preference, both field-based (FB) and volume-based 
(VB) PTVs were accepted as plan evaluation structures. 
As very few centres routinely contour breast CTV and PTV, centres 
were instructed in the trial protocol to generate a field-based PTV, 
defined 5 mm from the skin, 5 mm from the lung / chest wall 
interface, 5 mm from the posterior beam and 10 mm from the 
superior and inferior beam edges. 
The trial protocol stipulated that the dose distribution across the 
selected dose reporting volume should be within the ICRU guidelines 
of –5% to +7%, with a coverage limit of V95% ≥ 95% and high dose limits 
of V105% ≤ 5% and V107% ≤ 2%. 
Each retrospective individual case review was assessed on this basis. 
Results: To date 338 plans have been collected from 9 RT centres. 
Eight of these used a FB planning approach and only one contoured a 
CTV and PTV. 
Based on plan reviews and centre feedback the following differences 
between the two structures can be summarised: 
- The FB approach resulted in a 5% to 50% larger reporting volume 
which often included non-breast tissue, especially in the superior end 
of the volume. Planners reported difficulties achieving 95% coverage 
in the superior end. 
- The VB approach produced a structure that was anatomically 
relevant but extended further towards the sternum and often the 
medial part of the VB PTV had to be excluded from the fields. 
Initial analysis of 15 plans from the centre using VB planning indicated 
that: 
- The reported target coverage was worse for the FB PTV than for the 
VB PTV, which means that some plans were rejected as suboptimal 
based on a FB PTV that would otherwise have been accepted. 
- VB plans would sometimes have 105% hotspots outside the VB PTV, 
which would not be reflected in the DVH. The reported V105% was 
equally likely to be increased or decreased when moving to a FB PTV. 
- It was noted that the centre using the VB technique exhibited on 
average a higher lung V30% dose and had a greater number of 
percentage deviations for the lung objective. 
Conclusions: The analysis of the data collected so far shows that both 
FB and VB PTVs can be used as breast plan evaluation structures 
providing the discrepancies we have discovered are considered.  
Further planned work includes extending the sample of VB plans and 
adding data from more centres using the VB approach. A CTV will be 
contoured for an additional sample of FB plans in order to further 
analyse the effect of the planning approach on the amount of lung 
included in the treatment fields. 
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Purpose/Objective: Several prognostic scores had been proposed in 
the literature to predict patient survival for brain metastasis from 
breast cancer. However, which score is most appropriate for these 
patients are still unknown. The aim of the study was to compare the 
four prognostic indexes predicting survival: the Recursive Partition 
Analysis (RPA), the Basic Score for Brain Metastasis (BSBM), the 
Breast-Cancer-Specific GPA (BC-GPA) and the breast cancer RPA (BC-
RPA) (Table 1).  
Materials and Methods: Eighty-seven patients (median age 48) with 
brain metastasis from breast cancer were evaluated. All patients 
treated with WBRT with or without surgery, radiosurgery and systemic 
therapy between January 2000 and December 2011. Survival time was 
measured from the time of first treatment of BM to the date of death 
or last follow-up. Survival curves were calculated by using Kaplan-Meir 
method. To identify clinical factors associated with survival time, Cox 
proportional hazard model was used.  
 
 Results: Median survival time (MST) for all patients was 8 months. MST 
of patients in the RPA classes I, II, III were 12, 8.3 and 3.4 months, 
respectively (p=0.001). MST of patients in the BC-RPA class I was 
undetectably longer than that of the patients in BC-RPA class II (8 
months) and class III (3.4 months) (p=<0.0001). According to the BSBM 
scoring system, MST of patients with score 0,1,2 and 3 were 2, 5.5, 
8.3 and 26.5 months (p=0.051), respectively. According to the BC-GPA 
scoring system, MST of patients with scores ranging 0.5-1, 1.5-2, 2.5-3 
and 3.5-4 were 3.4, 5.5, 8 and 20 months (p=0.001), respectively. 
Although the pairwise comparison of adjacent groups was found 
significant for RPA index[subclass I vs. II (p=0.041), subclass II vs. III 
(p=0.016)] and BC-RPAindex [subclass I vs. II (p=0.004), subclass II vs. 
III (p=0.003)], there were no survival differences between some pairs 
of groups for BSBM index [subgroup 0 vs. 1 (p=0.435), subgroup 1 vs. 2 
(p=0.178), subgroup 2 vs. 3 (p=0.042)] and BC-GPA index [subgroup 
0.5-1 vs. 1.5-2 (p=0.947), subgroup 1.5-2 vs. 2.5-3 (p=0.144), subgroup 
2.5-3 vs. 3.5-4 (p=0.144)] indexes. Regarding the prognostic factors in 
our population, only the BC-RPA prognostic index was found 
independent predictor on survival (HR=5.11, p=0.01) within other 
indexes. 
Conclusions: In the present study, we compared four proposed 
prognostic indexes which of two, the BC-GPA and BC-RPA, were new. 
We validated the utility of RPA and BC-RPA prognostic indexesfor 
breast cancer patients with brain metastasis. A new index, BC-RPA 
was found more prognostic compared to other indexes. Further 
assessing of the BC-RPA in future trials and direct comparison of the 
indexes in studies with large number of patients answer the question, 
